3-Apr-2025
Novavax’s Regulatory Uncertainty and Market Potential: Hold Rating Maintained
TipRanks (Thu, 3-Apr 8:55 PM ET)
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Benzinga (Thu, 3-Apr 3:10 PM ET)
Novavax set to snap six days of losses as shares trade in green
Seeking Alpha News (Wed, 2-Apr 3:08 PM ET)
SA Asks: How will changes at FDA impact vaccine makers?
Seeking Alpha News (Wed, 2-Apr 2:56 PM ET)
Novavax bid for full approval of COVID vaccine stymied by FDA - report
Seeking Alpha News (Wed, 2-Apr 1:07 PM ET)
Marks’ Resignation Is a Blow for Biotech Industry, Says RBC Analyst
TipRanks (Tue, 1-Apr 12:25 AM ET)
How Peter Marks' FDA departure is impacting pharma, biotech stocks
Seeking Alpha News (Mon, 31-Mar 12:37 PM ET)
Biggest stock movers Monday: COOP, HSMT, CYRX, PCVX, MRNA, NNOX and more
Seeking Alpha News (Mon, 31-Mar 10:46 AM ET)
Novavax Announces Changes to Board of Directors
PRNewswire (Tue, 11-Mar 8:00 AM ET)
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
PRNewswire (Thu, 27-Feb 8:00 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of April 3, 2025, NVAX stock price declined to $5.60 with 5,918,261 million shares trading.
NVAX has a beta of 2.31, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.09 to the broad based SPY ETF.
NVAX has a market cap of $900.73 million. This is considered a Small Cap stock.
Last quarter Novavax reported $88 million in Revenue and -$.51 earnings per share. This beat revenue expectation by $4 million and met earnings estimates .
In the last 3 years, NVAX traded as high as $77.65 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): VTI, VB, IWM, VXF, XBI.
NVAX has outperformed the market in the last year with a return of +23.6%, while the SPY ETF gained +4.8%. However, in the most recent history, NVAX shares have underperformed the stock market with its stock returning -34.7% in the last 3 month period and -29.2% for the last 2 week period, while SPY has returned -7.9% and -5.1%, respectively.
NVAX support price is $5.75 and resistance is $6.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX shares will trade within this expected range on the day.